CClinicalTrials.gg
Status unknownNCT01353066EURDSSUpdated May 12, 2011

Gastric Bypass Versus Best Medical Treatment on Progression of Carotid-intima Media Thickness in Type 2 Diabetes Mellitus (T2DM)

A Phase 2/3 interventional study of Intensive Medical Treatment and IMM+Roux-en-Y Gastric Bypass (RYGBP) in Atherosclerotic Cardiovascular Disease and Subclinical Disease and/or Syndrome, sponsored by Hospital Clinic of Barcelona. Status unknown at 1 site in Spain. Open to participants aged 35 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-05-12.

Sponsored by Hospital Clinic of Barcelona · Phase 2/3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2011), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Phase 2/3
Study type
Interventional
Enrollment
240
Ages
35 Years to 65 Years
Sex
All
01

Study summary

Background: Type 2 Diabetes Mellitus (T2DM) is associated with an increased burden for cardiovascular disease (CVD). Multifactorial interventions are necessary to reduce the CV risk in T2DM. Bariatric surgery appears to be an alternative for the multifactorial intervention in T2DM associated with obesity. Data have shown, that clinical trial aiming at the control of CVRF in T2DM may not translate in the reduction of CV events.

Hypothesis: Intensive medical treatment (IMM) including Roux-en-Y Gastric Bypass (RYGBP) could be superior in the control of the progression of subclinical atherosclerotic disease, as evaluated by carotid ultrasound, in subjects with T2DM and a BMI between 30.0 and 34.9 kg/m2.The primary aim of the study is To compare the effects of intensive medical treatment (IMM) including Roux-en-Y Gastric Bypass (RYGBP) and IMM alone on the progression of the carotid intima media thickness (CIMT) at 24 months after entry into the trial relative to baseline.Methodology: Two-year Randomized Clinical Trial, including 240 patients

02

Conditions studied

  • Atherosclerotic Cardiovascular Disease
  • Subclinical Disease and/or Syndrome

Keywords

  • Type 2 Diabetes Mellitus
  • BMI 30.0-34.9 kg/m2
03

In context

Cardiovascular Diseases

4,904 studies on the registry are indexed under Cardiovascular Diseases; 919 are open to participants now.

This study's planned enrollment of 240 is above the median of 100 across 2,738 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Hospital Clinic of Barcelona is the lead sponsor of 319 studies on the registry; 55 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 65 Years
Sexes eligible
All

Inclusion criteria

  • Age 35 to 65 years at eligibility visit.
  • Diagnosed with T2DM at least 6 months prior to enrollment, under the active care of a doctor for at least he six months prior to enrollment, and HbA 1c > 7.0 %.
  • Current treatment for T2DM consisting of multiple doses of insulin with/without hypoglycemic agents or hypoglycemic agents plus basal insulin.
  • Optimization of diabetes medical treatment prior to inclusion in the study would have been performed based on best medical practices.
  • Body Mass Index (BMI)> 30.0 kg/m2 and \<34.9 kg/m2 at eligibility visit.
  • Willingness to accept random assignment to either treatment group.
  • Expect to live or work within approximately one hour's traveling time from the study clinic for the duration of the two-year trial.
  • Willingness to comply with the follow-up protocol and successful completion of the run-in.
  • Written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Cardiovascular event (myocardial infarction, acute coronary syndrome, coronary artery angioplasty or bypass, stroke) in the past six months.
  • Current evidence of congestive heart failure (grade II or IV), angina pectoris, symptomatic peripheral vascular disease or advanced cardiovascular disease.
  • History of severe hypoglycemic episodes associated with medical treatment of type 2 DM
  • Cardiac stress test indicating that surgery would not be safe
  • Pulmonary embolus or thrombophlebitis in the past six months.
  • Cancer of any kind (except basal cell skin cancer or cancer in situ) unless documented to be disease-free for five years.
  • Significant anemia or history of coagulopathy.
  • Serum creatinine >1.5 mg/dl.
  • Serum total bilirubin or alkaline phosphatase greater than the upper limit of normal, or ALT greater than twice the upper limit of normal.
  • History of previous surgery contraindicating gastric bypass at the criteria of the surgical team.
  • Gastric or duodenal ulcer in the past six months.
  • History of intra-abdominal sepsis (except for uncomplicated appendicitis or diverticulitis more than six months prior to enrollment).
  • Previous organ transplantation.
  • Self-reported HIV-positive status, active tuberculosis, active malaria, chronic hepatitis B or C, cirrhosis, or inflammatory bowel disease.
  • Currently pregnant or nursing, or planning to become pregnant in the next two years.
  • History of alcohol or drug dependency (excluding caffeine and nicotine) in the past five years
  • Active psychosocial or psychiatric problem that is likely to interferer with adherence to the protocol.
  • Score of 17 or higher on the CES-D (depression scale).
  • Current participation in a conflicting research protocol.
  • Presence of any chronic or debilitating disease that would make adherence to the protocol difficult.
  • 12-lead EKG indicating that surgery or intensive medical treatment would not be safe.
  • Diagnosed with diabetes more than 15 years ago.
  • Positive GAD antibodies
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Enrollment
240 participants (estimated)

Study arms

  • Active comparator
    Intensive Medical Treatment

    Drug: Intensive Medical Treatment

  • Experimental
    Intensive medical treatment (IMM)+RYGBP

    Other: IMM+Roux-en-Y Gastric Bypass (RYGBP)

Interventions

  • DrugIntensive Medical Treatment
  • OtherIMM+Roux-en-Y Gastric Bypass (RYGBP)
06

What researchers measure

Primary outcomes

  1. Measurement of the progression carotid intima media thickness (CIMT) at 24 months after entry into the trial relative to baseline

    Time frame: 24 months

07

Study locations

1 site
  • Hospital Clínic de Barcelona
    Barcelona, Catalunya 08036, Spain
    • Josep Vidal, MD · Principal investigator
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 12, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01353066
Lead sponsor
Hospital Clinic of Barcelona
First posted
May 12, 2011
Last update
May 12, 2011

Study contacts

Antonio M Lacy, MD
Contact
steres@clinic.ub.es
+34932279854
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion